Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL)
| Autor: | S. M. Ansell, Sandra J. Horning, Matthew J. Maurer, Susan Geyer, U. Gayko, Thomas M. Habermann, A. Cesano, Ivana N. Micallef, David J. Inwards, Brad S. Kahl |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment CHOP Neutropenia medicine.disease Surgery Tolerability hemic and lymphatic diseases Internal medicine medicine Rituximab Progression-free survival business Epratuzumab Diffuse large B-cell lymphoma medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:6580-6580 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 6580 Background: A pilot study was performed at Mayo Clinic Rochester and University of Wisconsin Madison, to assess the feasibility of combination ER-CHOP in patients (pts) with newly diagnosed DLBCL. Methods: Therapy was given as follows: Epratuzumab 360mg/m2 followed by Rituximab 375 mg/m2 and standard dose CHOP q 3 weeks for 6–8 cycles. Primary endpoint was safety and tolerability as determined by the incidence of grade 4 neutropenia and grade 3–4 antibody infusional toxicity; secondary endpoints were efficacy as determined by the CR rates, overall response rates (ORR) and 9-month progression free survival. Weekly CBCs were obtained to monitor hematological toxicity. Growth factor (GF) support was added to subsequent cycles for all pts who experienced grade 4 neutropenia. Subsequent neutropenia mandated a dose reduction of chemotherapy. Results: As of December 2003, all 15 pts have been entered on protocol. Baseline pt characteristics included median age 63 years (range 42–78); 10 pts (67%) were male.... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|